Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy

MT Newswires Live

May 26

Olema Pharmaceuticals (OLMA) said Tuesday it entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its investigational therapy OP-3136 in combination with Bayer's Nubeqa in patients with metastatic castration-resistant prostate cancer.

Financial terms were not provided.

Under the terms of the deal, Bayer will supply Nubeqa for use in a phase 1b/2 study that Olema will lead, Olema said.

All clinical data and inventions related to the combined use of the drugs will be jointly owned, Olema said, adding it will retain global commercial and marketing rights to OP-3136.

The phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination therapy in around 36 patients, Olema said.

Shares of Olema were up 1.9% in premarket activity Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2638417511"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2638417511\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2638417511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 19:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2638417511","market":"sg","top_or_hot":-1,"title":"Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy","media":"MT Newswires Live","content":"<html><body><p> Olema Pharmaceuticals (OLMA) said Tuesday it entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its investigational therapy OP-3136 in combination with Bayer's Nubeqa in patients with metastatic castration-resistant prostate cancer.</p><p>Financial terms were not provided.</p><p>Under the terms of the deal, Bayer will supply Nubeqa for use in a phase 1b/2 study that Olema will lead, Olema said.</p><p>All clinical data and inventions related to the combined use of the drugs will be jointly owned, Olema said, adding it will retain global commercial and marketing rights to OP-3136.</p><p>The phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination therapy in around 36 patients, Olema said.</p><p>Shares of Olema were up 1.9% in premarket activity Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Olema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOlema Pharmaceuticals, Bayer Collaborate to Test Potential Prostate Cancer Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-26 19:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Olema Pharmaceuticals (OLMA) said Tuesday it entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its investigational therapy OP-3136 in combination with Bayer's Nubeqa in patients with metastatic castration-resistant prostate cancer.</p><p>Financial terms were not provided.</p><p>Under the terms of the deal, Bayer will supply Nubeqa for use in a phase 1b/2 study that Olema will lead, Olema said.</p><p>All clinical data and inventions related to the combined use of the drugs will be jointly owned, Olema said, adding it will retain global commercial and marketing rights to OP-3136.</p><p>The phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination therapy in around 36 patients, Olema said.</p><p>Shares of Olema were up 1.9% in premarket activity Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2638417511","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2638417511","pubTimestamp":1779796496,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Olema Pharmaceuticals  said Tuesday it entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its investigational therapy OP-3136 in combination with Bayer's Nubeqa in patients with metastatic castration-resistant prostate cancer.Financial terms were not provided.Under the terms of the deal, Bayer will supply Nubeqa for use in a phase 1b/2 study that Olema will lead, Olema said.All clinical data and inventions related to the combined use of the drugs will be jointly owned, Olema said, adding it will retain global commercial and marketing rights to OP-3136.The phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination therapy in around 36 patients, Olema said.Shares of Olema were up 1.9% in premarket activity Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","BK4139":"生物科技","OLMA":"Olema Pharmaceuticals, Inc."},"translate_title":"Olema Pharmaceuticals与拜耳合作测试潜在的前列腺癌联合疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OLMA":1.5},"content_text":"Olema Pharmaceuticals (OLMA) said Tuesday it entered into a clinical trial collaboration and supply agreement with Bayer to evaluate its investigational therapy OP-3136 in combination with Bayer's Nubeqa in patients with metastatic castration-resistant prostate cancer.Financial terms were not provided.Under the terms of the deal, Bayer will supply Nubeqa for use in a phase 1b/2 study that Olema will lead, Olema said.All clinical data and inventions related to the combined use of the drugs will be jointly owned, Olema said, adding it will retain global commercial and marketing rights to OP-3136.The phase 1b/2 study is designed to assess the safety, tolerability, and preliminary anti-tumor activity of the combination therapy in around 36 patients, Olema said.Shares of Olema were up 1.9% in premarket activity Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}